Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 290 articles:
HTML format
Text format



Single Articles


    March 2019
  1. JACKSON B, Begun J, Gray K, Churilov L, et al
    Clinical decision support improves quality of care in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2019 Mar 7. doi: 10.1111/apt.15209.
    PubMed     Text format     Abstract available


  2. GIBSON DJ, Ward MG
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
    Aliment Pharmacol Ther. 2019;49:816-817.
    PubMed     Text format    


  3. BOUGUEN G, Siproudhis L
    Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.
    Aliment Pharmacol Ther. 2019;49:817-818.
    PubMed     Text format    


    February 2019
  4. BANK S, Julsgaard M, Abed OK, Burisch J, et al
    Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 27. doi: 10.1111/apt.15187.
    PubMed     Text format     Abstract available


  5. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 19. doi: 10.1111/apt.15179.
    PubMed     Text format     Abstract available


  6. SHIVAJI UN, Sharratt CL, Thomas T, Smith SCL, et al
    Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15097.
    PubMed     Text format     Abstract available


  7. SHAH A, Morrison M, Burger D, Martin N, et al
    Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 8. doi: 10.1111/apt.15133.
    PubMed     Text format     Abstract available


  8. CHEN P, Li Y, Li L, Yu Q, et al
    Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019 Feb 7. doi: 10.1111/apt.15159.
    PubMed     Text format     Abstract available


  9. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2019;49:477-478.
    PubMed     Text format    


  10. AHMED T, Brown F, Ahmed R, Shah A, et al
    Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2019;49:476-477.
    PubMed     Text format    


    January 2019
  11. KESHTELI AH, Madsen KL, Mandal R, Boeckxstaens GE, et al
    Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.
    Aliment Pharmacol Ther. 2019 Jan 31. doi: 10.1111/apt.15141.
    PubMed     Text format     Abstract available


  12. GHERSIN I, Khteeb N, Katz LH, Daher S, et al
    Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.
    Aliment Pharmacol Ther. 2019 Jan 27. doi: 10.1111/apt.15160.
    PubMed     Text format     Abstract available


  13. OSTERMAN MT, Rosario M, Lasch K, Barocas M, et al
    Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15113.
    PubMed     Text format     Abstract available


  14. AGRAWAL M, Cohen-Mekelburg S, Kayal M, Axelrad J, et al
    Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors.
    Aliment Pharmacol Ther. 2019 Jan 20. doi: 10.1111/apt.15107.
    PubMed     Text format     Abstract available


  15. CHAPARRO M, Garre A, Ricart E, Iglesias-Flores E, et al
    Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU.
    Aliment Pharmacol Ther. 2019 Jan 13. doi: 10.1111/apt.15114.
    PubMed     Text format     Abstract available


  16. ASHTON JJ, Borca F, Mossotto E, Coelho T, et al
    Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.
    Aliment Pharmacol Ther. 2019 Jan 9. doi: 10.1111/apt.15094.
    PubMed     Text format     Abstract available


  17. LUCIDARME C, Petitcollin A, Brochard C, Siproudhis L, et al
    Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Aliment Pharmacol Ther. 2019;49:147-154.
    PubMed     Text format     Abstract available


    December 2018
  18. MA C, Guizzetti L, Cipriano LE, Parker CE, et al
    Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies.
    Aliment Pharmacol Ther. 2018 Dec 19. doi: 10.1111/apt.15090.
    PubMed     Text format     Abstract available


  19. PARK SW, Kim TJ, Lee JY, Kim ER, et al
    Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study.
    Aliment Pharmacol Ther. 2018 Dec 2. doi: 10.1111/apt.15076.
    PubMed     Text format     Abstract available


  20. KAMM MA
    Editorial: treating strictures in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48.
    PubMed     Text format    


  21. RIEDER F, Feagan BG, Jairath V
    Editorial: treating strictures in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48.
    PubMed     Text format    


    November 2018
  22. SITTE J, Frentiu E, Baumann C, Rousseau H, et al
    Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.
    Aliment Pharmacol Ther. 2018 Nov 28. doi: 10.1111/apt.15057.
    PubMed     Text format     Abstract available


  23. NOURELDIN M, Higgins PDR, Govani SM, Cohen-Mekelburg S, et al
    Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.
    Aliment Pharmacol Ther. 2018 Nov 14. doi: 10.1111/apt.15023.
    PubMed     Text format     Abstract available


  24. PUREWAL S, Chapman S, Czuber-Dochan W, Selinger C, et al
    Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health.
    Aliment Pharmacol Ther. 2018 Nov 8. doi: 10.1111/apt.15019.
    PubMed     Text format     Abstract available


  25. ORFANOUDAKI E, Drygiannakis I, Koutroubakis IE
    Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Aliment Pharmacol Ther. 2018;48:1037-1038.
    PubMed     Text format    


  26. HANS AK, Scott FI
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection?
    Aliment Pharmacol Ther. 2018;48:1158-1159.
    PubMed     Text format    


  27. POTTER MD, Walker MM, Jones MP, Koloski NA, et al
    Letter: gluten sensitivity in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1167-1168.
    PubMed     Text format    


  28. DE FRANCISCO R, Castano-Garcia A, Riestra S
    Editorial: which inflammatory bowel disease patients should be screened for Epstein-Barr virus infection? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:1159-1160.
    PubMed     Text format    


  29. AL SULAIS E, AlAmeel T
    Letter: faecal calprotectin, clinical indices and the diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:1166.
    PubMed     Text format    


    October 2018
  30. STEVENS TW, Matheeuwsen M, Lonnkvist MH, Parker CE, et al
    Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15033.
    PubMed     Text format     Abstract available


  31. PASCHOS P, Katsoula A, Salanti G, Giouleme O, et al
    Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life.
    Aliment Pharmacol Ther. 2018 Oct 30. doi: 10.1111/apt.15005.
    PubMed     Text format     Abstract available


  32. CHU TPC, Grainge MJ, Card TR
    The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity.
    Aliment Pharmacol Ther. 2018 Oct 8. doi: 10.1111/apt.15010.
    PubMed     Text format     Abstract available


  33. PHILPOTT H, Dougherty MK, Dellon ES
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:885-886.
    PubMed     Text format    


  34. CHAPARRO M, Garre A, Ricart E, Iborra M, et al
    Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2018;48:839-851.
    PubMed     Text format     Abstract available


  35. WOOD P, Henderson P
    Letter: screening for adrenal suppression in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:884-885.
    PubMed     Text format    


    September 2018
  36. CANETE F, Manosa M, Clos A, Cabre E, et al
    Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Sep 4. doi: 10.1111/apt.14956.
    PubMed     Text format     Abstract available


  37. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Editorial: anxiety and depression in inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2018;48:687-688.
    PubMed     Text format    


  38. LEE HH, Bae JM, Lee BI
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first-line therapy in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2018;48:684-685.
    PubMed     Text format    


  39. PARIENTE B, Blondeaux A
    Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:683-684.
    PubMed     Text format    


  40. MIKOCKA-WALUS A, Knowles SR
    Editorial: anxiety and depression in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:686-687.
    PubMed     Text format    


  41. WEINBERG EM, Reddy KR
    Editorial: leave it unhooked? Possible benefits of ileostomy over ileal-pouch-anal anastomosis in patients with ulcerative colitis and primary sclerosing cholangitis in the setting of liver transplantation.
    Aliment Pharmacol Ther. 2018;48:581-582.
    PubMed     Text format    


    August 2018
  42. DE FRANCISCO R, Castano-Garcia A, Martinez-Gonzalez S, Perez-Martinez I, et al
    Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Aug 10. doi: 10.1111/apt.14933.
    PubMed     Text format     Abstract available


  43. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID.
    Aliment Pharmacol Ther. 2018 Aug 2. doi: 10.1111/apt.14926.
    PubMed     Text format     Abstract available


  44. SAVOYE G, Fumery M, Gower-Rousseau C
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:384-385.
    PubMed     Text format    


  45. JULSGAARD M, Kjeldsen J, Brock B, Baumgart DC, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:386-388.
    PubMed     Text format    


  46. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:388-389.
    PubMed     Text format    


  47. MYRELID P
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery?
    Aliment Pharmacol Ther. 2018;48:383-384.
    PubMed     Text format    


  48. PEYRIN-BIROULET L, Lopez A, Cummings JRF, Dignass A, et al
    Review article: treating-to-target for inflammatory bowel disease-associated anaemia.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14922.
    PubMed     Text format     Abstract available


  49. ERIKSSON C, Henriksson I, Brus O, Zhulina Y, et al
    Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14920.
    PubMed     Text format     Abstract available


    July 2018
  50. KOTZE PG, Ma C, Almutairdi A, Al-Darmaki A, et al
    Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 31. doi: 10.1111/apt.14919.
    PubMed     Text format     Abstract available


  51. JOOSSE ME, Aardoom MA, Kemos P, Turner D, et al
    Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14893.
    PubMed     Text format     Abstract available


  52. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14865.
    PubMed     Text format     Abstract available


  53. ANSARI AR, Aziz A
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:97-98.
    PubMed     Text format    


  54. FRIEDMAN AB, Sparrow MP
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:98-99.
    PubMed     Text format    


    June 2018
  55. HANLON I, Hewitt C, Bell K, Phillips A, et al
    Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14840.
    PubMed     Text format     Abstract available


  56. VAN DEN BRINK G, Stapersma L, Vlug LE, Rizopolous D, et al
    Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14832.
    PubMed     Text format     Abstract available


  57. PARK KT, Sceats L, Dehghan M, Trickey AW, et al
    Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 7. doi: 10.1111/apt.14842.
    PubMed     Text format     Abstract available


  58. GONCALVES J, Santos M, Acurcio R, Iria I, et al
    Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14808.
    PubMed     Text format     Abstract available


  59. BAE JM, Lee HH, Lee BI, Lee KM, et al
    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14822.
    PubMed     Text format     Abstract available


  60. ALUKAIDEY S, Heerasing N
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice.
    Aliment Pharmacol Ther. 2018;47:1539-1540.
    PubMed     Text format    


  61. UNGARO R, Colombel JF
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1540.
    PubMed     Text format    


    May 2018
  62. TSE CS, Loftus EV Jr, Raffals LE, Gossard AA, et al
    Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 May 28. doi: 10.1111/apt.14829.
    PubMed     Text format     Abstract available


  63. SACLEUX SC, Sarter H, Fumery M, Charpentier C, et al
    Post-operative complications in elderly onset inflammatory bowel disease: a population-based study.
    Aliment Pharmacol Ther. 2018 May 8. doi: 10.1111/apt.14790.
    PubMed     Text format     Abstract available


  64. SEHGAL P, Colombel JF, Aboubakr A, Narula N, et al
    Systematic review: safety of mesalazine in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 May 3. doi: 10.1111/apt.14688.
    PubMed     Text format     Abstract available


  65. FRAGAKI M, Karmiris K
    Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease-following the fate of anti-TNF-alpha agents?
    Aliment Pharmacol Ther. 2018;47:1323-1324.
    PubMed     Text format    


  66. PAVLIDIS P, Graham J, Gulati S, Dubois P, et al
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1422-1423.
    PubMed     Text format    


  67. MANOSA M, Domenech E
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1421-1422.
    PubMed     Text format    


  68. CHRISTENSEN B, Gibson PR, Rubin DT
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1423-1424.
    PubMed     Text format    


  69. EVERHOV AH, Ludvigsson JF, Olen O
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1420-1421.
    PubMed     Text format    


    April 2018
  70. MA C, Guizzetti L, Panaccione R, Fedorak RN, et al
    Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 25. doi: 10.1111/apt.14672.
    PubMed     Text format     Abstract available


  71. WHITE JR, Phillips F, Monaghan T, Fateen W, et al
    Review article: novel oral-targeted therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Apr 19. doi: 10.1111/apt.14669.
    PubMed     Text format     Abstract available


  72. KURNOOL S, Nguyen NH, Proudfoot J, Dulai PS, et al
    High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14665.
    PubMed     Text format     Abstract available


  73. MONINUOLA OO, Milligan W, Lochhead P, Khalili H, et al
    Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
    Aliment Pharmacol Ther. 2018 Apr 5. doi: 10.1111/apt.14606.
    PubMed     Text format     Abstract available


  74. TALEBAN S
    Editorial: older-onset inflammatory bowel disease-is it time to start looking beyond a number?
    Aliment Pharmacol Ther. 2018;47:1034-1035.
    PubMed     Text format    


  75. MAGRO F, Sousa HT
    Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures.
    Aliment Pharmacol Ther. 2018;47:1033-1034.
    PubMed     Text format    


    March 2018
  76. TANG MT, Keir ME, Erickson R, Stefanich EG, et al
    Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 30. doi: 10.1111/apt.14631.
    PubMed     Text format     Abstract available


  77. VOLLEBREGT PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, et al
    Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 9. doi: 10.1111/apt.14599.
    PubMed     Text format     Abstract available


  78. UNGARO R, Fausel R, Chang HL, Chang S, et al
    Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study.
    Aliment Pharmacol Ther. 2018 Mar 7. doi: 10.1111/apt.14569.
    PubMed     Text format     Abstract available


  79. WALKER GJ, Moore L, Heerasing N, Hendy P, et al
    Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
    Aliment Pharmacol Ther. 2018 Mar 5. doi: 10.1111/apt.14563.
    PubMed     Text format     Abstract available


  80. LAHARIE D, Riviere P
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:689-690.
    PubMed     Text format    


  81. QIU XY, Lu MJ, Zhang HJ
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:690-691.
    PubMed     Text format    


  82. LOBATON T, De Vos M
    Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Aliment Pharmacol Ther. 2018;47:855-856.
    PubMed     Text format    


  83. DE SIMONE C
    Letter: what gastroenterologists should know about VSL#3.
    Aliment Pharmacol Ther. 2018;47:698-699.
    PubMed     Text format    


  84. WILS P, Bouhnik Y, Michetti P, Flourie B, et al
    Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Aliment Pharmacol Ther. 2018;47:588-595.
    PubMed     Text format     Abstract available


  85. LIGHTNER AL, McKenna NP, Tse CS, Raffals LE, et al
    Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
    Aliment Pharmacol Ther. 2018;47:573-580.
    PubMed     Text format     Abstract available


  86. SINGH S, Andersen NN, Andersson M, Loftus EV Jr, et al
    Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn's disease: a population-based Danish cohort study.
    Aliment Pharmacol Ther. 2018;47:596-604.
    PubMed     Text format     Abstract available


    February 2018
  87. BARRE A, Colombel JF, Ungaro R
    Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14550.
    PubMed     Text format     Abstract available


  88. BALLOU S, Hirsch W, Singh P, Rangan V, et al
    Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.
    Aliment Pharmacol Ther. 2018 Feb 7. doi: 10.1111/apt.14551.
    PubMed     Text format     Abstract available


  89. GORDON IO, Agrawal N, Willis E, Goldblum JR, et al
    Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation.
    Aliment Pharmacol Ther. 2018 Feb 6. doi: 10.1111/apt.14526.
    PubMed     Text format     Abstract available


  90. RIBALDONE DG, Saracco GM, Astegiano M, Pellicano R, et al
    Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Aliment Pharmacol Ther. 2018;47:448-449.
    PubMed     Text format    


  91. COTE-DAIGNEAULT J, Luong ML, Colombel JF, Peerani F, et al
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2018;47:446-447.
    PubMed     Text format    


  92. KHAN N, Lewis JD
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply.
    Aliment Pharmacol Ther. 2018;47:448.
    PubMed     Text format    


  93. PAPAMICHAEL K, Cheifetz AS
    Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:436-437.
    PubMed     Text format    


  94. TSAI HH
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Aliment Pharmacol Ther. 2018;47:539-540.
    PubMed     Text format    


  95. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:540-541.
    PubMed     Text format    


  96. BARCLAY ML, Stamp LK
    Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:535-536.
    PubMed     Text format    


  97. PRIMAS C, Reinisch S, Novacek G
    Letter: addition of azathioprine to infliximab maintenance therapy in patients with anti-drug antibodies and subclinical inflammation.
    Aliment Pharmacol Ther. 2018;47:544-545.
    PubMed     Text format    


  98. TAO P, Wang SY
    Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
    Aliment Pharmacol Ther. 2018;47:443.
    PubMed     Text format    


  99. SABINO J, Torres J
    Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2018;47:439-440.
    PubMed     Text format    


  100. JALANKA J, Hillamaa A, Satokari R, Mattila E, et al
    The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection.
    Aliment Pharmacol Ther. 2018;47:371-379.
    PubMed     Text format     Abstract available


  101. DREESEN E, Van Stappen T, Ballet V, Peeters M, et al
    Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Aliment Pharmacol Ther. 2018;47:346-355.
    PubMed     Text format     Abstract available


    January 2018
  102. YACOUB W, Williet N, Pouillon L, Di-Bernado T, et al
    Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Aliment Pharmacol Ther. 2018 Jan 31. doi: 10.1111/apt.14548.
    PubMed     Text format     Abstract available


  103. CHRISTENSEN B, Micic D, Gibson PR, Yarur A, et al
    Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14525.
    PubMed     Text format     Abstract available


  104. MANOSA M, Calafat M, de Francisco R, Garcia C, et al
    Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
    Aliment Pharmacol Ther. 2018 Jan 25. doi: 10.1111/apt.14494.
    PubMed     Text format     Abstract available


  105. WALJEE AK, Liu B, Sauder K, Zhu J, et al
    Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14510.
    PubMed     Text format     Abstract available


  106. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Meade L, et al
    Systematic review: psychosocial factors associated with pain in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14493.
    PubMed     Text format     Abstract available


  107. OLIVERA P, Sandborn WJ, Panes J, Baumann C, et al
    Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
    Aliment Pharmacol Ther. 2018 Jan 19. doi: 10.1111/apt.14514.
    PubMed     Text format     Abstract available


  108. COLIZZO FP, Friedman LS
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:143-144.
    PubMed     Text format    


  109. BROEKMAN MMTJ, Wanten GJ, de Jong DJ
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:130-131.
    PubMed     Text format    


  110. SELINGER CP, Parkes GC, Raine T
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease-Author's reply.
    Aliment Pharmacol Ther. 2018;47:145.
    PubMed     Text format    


  111. WILLINGTON AJ, Gearry RB
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.
    Aliment Pharmacol Ther. 2018;47:129-130.
    PubMed     Text format    


  112. MURRAY CD
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine.
    Aliment Pharmacol Ther. 2018;47:141-142.
    PubMed     Text format    


  113. MEIJER B, de Boer NKH
    Letter: thiopurines - is less really more?
    Aliment Pharmacol Ther. 2018;47:149.
    PubMed     Text format    


  114. DING NS, Malietzis G, Hart AL
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:142-143.
    PubMed     Text format    


  115. EBERHARDSON M, Soderling JK, Olen O
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:147-148.
    PubMed     Text format    


  116. RIBALDONE DG, Saracco G, Astegiano M, Pellicano R, et al
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?
    Aliment Pharmacol Ther. 2018;47:146-147.
    PubMed     Text format    


  117. LANG BM, Biedermann L, van Haaften WT, de Valliere C, et al
    Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:55-66.
    PubMed     Text format     Abstract available


  118. VANDE CASTEELE N, Feagan BG, Vermeire S, Yassine M, et al
    Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:229-237.
    PubMed     Text format     Abstract available


  119. BAR-YOSEPH H, Levhar N, Selinger L, Manor U, et al
    Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Aliment Pharmacol Ther. 2018;47:212-218.
    PubMed     Text format     Abstract available


  120. NORDENVALL C, Olen O, Nilsson PJ, von Seth E, et al
    Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.
    Aliment Pharmacol Ther. 2018;47:238-245.
    PubMed     Text format     Abstract available


  121. ADAMS A, Kalla R, Satsangi J
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD.
    Aliment Pharmacol Ther. 2018;47:306-307.
    PubMed     Text format    


  122. SAWBRIDGE D, Subramanian S
    Editorial: the IBD-disability index-ready for prime time?
    Aliment Pharmacol Ther. 2018;47:298-299.
    PubMed     Text format    


  123. LANG BM, Beerenwinkel N, Misselwitz B
    Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:307-308.
    PubMed     Text format    


    December 2017
  124. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14483.
    PubMed     Text format     Abstract available


  125. TADBIRI S, Peyrin-Biroulet L, Serrero M, Filippi J, et al
    Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Aliment Pharmacol Ther. 2017 Dec 18. doi: 10.1111/apt.14419.
    PubMed     Text format     Abstract available


  126. PAPAMICHAEL K, Rakowsky S, Rivera C, Cheifetz AS, et al
    Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 6. doi: 10.1111/apt.14458.
    PubMed     Text format     Abstract available


  127. SCHMITZ EMH, Boekema PJ, Straathof JWA, van Renswouw DC, et al
    Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14453.
    PubMed     Text format     Abstract available


  128. LU MJ, Qiu XY, Mao XQ, Li XT, et al
    Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14436.
    PubMed     Text format     Abstract available


  129. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14449.
    PubMed     Text format     Abstract available


  130. SINGH S, Fumery M, Sandborn WJ, Murad MH, et al
    Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14422.
    PubMed     Text format     Abstract available


  131. LOGAN M, Ijaz UZ, Hansen R, Gerasimidis K, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  132. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  133. DOMENECH E, Canete F, Manosa M
    Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  134. MARTINEAU C, Flourie B, Wils P, Vaysse T, et al
    Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format     Abstract available


  135. MITREV N, Vande Casteele N, Seow CH, Andrews JM, et al
    Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format     Abstract available


    November 2017
  136. YU H, MacIsaac D, Wong JJ, Sellers ZM, et al
    Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2017 Nov 22. doi: 10.1111/apt.14430.
    PubMed     Text format     Abstract available


  137. COLOMBEL JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, et al
    Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Nov 21. doi: 10.1111/apt.14420.
    PubMed     Text format     Abstract available


  138. AYUBI E, Safiri S
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017;46:901-902.
    PubMed     Text format    


  139. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:902-903.
    PubMed     Text format    


  140. GOUYNOU C, Peyrin-Biroulet L
    Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
    Aliment Pharmacol Ther. 2017;46:1019-1020.
    PubMed     Text format    


  141. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1026-1027.
    PubMed     Text format    


  142. DAI C, Cao Q, Jiang M
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:1025-1026.
    PubMed     Text format    


  143. FIORINO G, Correale C, Radice S, Allocca M, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Aliment Pharmacol Ther. 2017;46:903-905.
    PubMed     Text format    


  144. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:897-898.
    PubMed     Text format    


  145. KOMAKI Y, Yamada A, Komaki F, Sakuraba A, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2017;46:905-906.
    PubMed     Text format    


  146. H ALLIN K, Jess T
    Editorial: do thiopurines and biologics decrease the risk of colectomy?
    Aliment Pharmacol Ther. 2017;46:896-897.
    PubMed     Text format    


  147. NAKASE H, Motoya S, Matsumoto T, Watanabe K, et al
    Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Aliment Pharmacol Ther. 2017;46:873-882.
    PubMed     Text format     Abstract available


  148. DING NS, Malietzis G, Lung PFC, Penez L, et al
    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.
    Aliment Pharmacol Ther. 2017;46:883-891.
    PubMed     Text format     Abstract available


  149. CARDING SR, Davis N, Hoyles L
    Review article: the human intestinal virome in health and disease.
    Aliment Pharmacol Ther. 2017;46:800-815.
    PubMed     Text format     Abstract available


    October 2017
  150. KUMP P, Wurm P, Grochenig HP, Wenzl H, et al
    The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Oct 20. doi: 10.1111/apt.14387.
    PubMed     Text format     Abstract available


  151. MCILROY J, Ianiro G, Mukhopadhya I, Hansen R, et al
    Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    Aliment Pharmacol Ther. 2017 Oct 16. doi: 10.1111/apt.14384.
    PubMed     Text format     Abstract available


  152. LO B, Prosberg MV, Gluud LL, Chan W, et al
    Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
    Aliment Pharmacol Ther. 2017 Oct 9. doi: 10.1111/apt.14373.
    PubMed     Text format     Abstract available


  153. SWAMINATH A, Feathers A, Ananthakrishnan AN, Falzon L, et al
    Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:645-656.
    PubMed     Text format     Abstract available


  154. ACTIS GC, Pellicano R
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset.
    Aliment Pharmacol Ther. 2017;46:768.
    PubMed     Text format    


  155. DAMAS O, Abreu MT
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:768-769.
    PubMed     Text format    


  156. LUNG PFC, Ng SC
    Editorial: challenges in the development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:696.
    PubMed     Text format    


    September 2017
  157. BERNSTEIN CN
    Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14338.
    PubMed     Text format     Abstract available


  158. SELINGER CP, Parkes GC, Bassi A, Fogden E, et al
    A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14334.
    PubMed     Text format     Abstract available


  159. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
    Aliment Pharmacol Ther. 2017 Sep 15. doi: 10.1111/apt.14323.
    PubMed     Text format     Abstract available


  160. XU L, Lochhead P, Ko Y, Claggett B, et al
    Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14291.
    PubMed     Text format     Abstract available


  161. ALEXAKIS C, Kumar S, Saxena S, Hotopf M, et al
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply.
    Aliment Pharmacol Ther. 2017;46:554-555.
    PubMed     Text format    


  162. KEEFER L
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care.
    Aliment Pharmacol Ther. 2017;46:553-554.
    PubMed     Text format    


  163. GRACIE DJ, Derwa Y, Hamlin PJ, Ford AC, et al
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:633-634.
    PubMed     Text format    


  164. SHANAHAN F
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?
    Aliment Pharmacol Ther. 2017;46:632-633.
    PubMed     Text format    


  165. LIM MH, Radford-Smith GL
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet?
    Aliment Pharmacol Ther. 2017;46:630-631.
    PubMed     Text format    


  166. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:631-632.
    PubMed     Text format    


  167. EBERHARDSON M, Soderling JK, Neovius M, Cars T, et al
    Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
    Aliment Pharmacol Ther. 2017;46:589-598.
    PubMed     Text format     Abstract available


  168. SAMAAN MA, Puylaert CAJ, Levesque BG, Zou GY, et al
    The development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:516-528.
    PubMed     Text format     Abstract available


  169. SPEIGHT RA, Mansfield JC
    Editorial: how effective is vedolizumab in the 'real world'?
    Aliment Pharmacol Ther. 2017;46:555-556.
    PubMed     Text format    


    August 2017
  170. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010.
    Aliment Pharmacol Ther. 2017 Aug 17. doi: 10.1111/apt.14268.
    PubMed     Text format     Abstract available


  171. KHAN N, Shah Y, Trivedi C, Lewis JD, et al
    Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2017 Aug 14. doi: 10.1111/apt.14257.
    PubMed     Text format     Abstract available


  172. DAMAS OM, Schwartz SJ, Abreu MT
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2017;46:467.
    PubMed     Text format    


  173. KUENZIG ME, Benchimol EI
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;46:465-466.
    PubMed     Text format    


  174. WISKIN AE, Sandhu BK
    Editorial: changing nature of paediatric IBD-new insights from Irish data.
    Aliment Pharmacol Ther. 2017;46:457-458.
    PubMed     Text format    


  175. SEOW CH, Panaccione R
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
    Aliment Pharmacol Ther. 2017;46:463-464.
    PubMed     Text format    


  176. HUSSEY S
    Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Aliment Pharmacol Ther. 2017;46:458-459.
    PubMed     Text format    


  177. WARD MG, Irving PM
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:465.
    PubMed     Text format    


  178. WILLIAMS HRT, Orchard TR
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential.
    Aliment Pharmacol Ther. 2017;46:371-372.
    PubMed     Text format    


  179. SMOLINSKA A, van Schooten FJ
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:372.
    PubMed     Text format    


    July 2017
  180. COATES MD, Tekin I, Vrana KE, Mawe GM, et al
    Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jul 24. doi: 10.1111/apt.14226.
    PubMed     Text format     Abstract available


  181. UNGARO RC, Colombel JF
    Editorial: biologics in inflammatory bowel disease-time for direct comparisons.
    Aliment Pharmacol Ther. 2017;46:68-69.
    PubMed     Text format    


  182. ANDREWS JM
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?
    Aliment Pharmacol Ther. 2017;46:201-202.
    PubMed     Text format    


  183. CRAMER H, Dobos G, Langhorst J
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:202-203.
    PubMed     Text format    


  184. VAN HAAFTEN WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, et al
    Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:26-39.
    PubMed     Text format     Abstract available


  185. WARD MG, Warner B, Unsworth N, Chuah SW, et al
    Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Aliment Pharmacol Ther. 2017;46:150-161.
    PubMed     Text format     Abstract available


  186. ANANTHAKRISHNAN AN, Sakuraba A, Barnes EL, Pekow J, et al
    The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:162-168.
    PubMed     Text format     Abstract available


  187. IMPERATORE N, Testa A, Caporaso N, Rispo A, et al
    Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
    Aliment Pharmacol Ther. 2017;46:212.
    PubMed     Text format    


  188. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Editorial: which iron preparation for patients with IBD? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:195-196.
    PubMed     Text format    


  189. KENNEDY NA, Goodhand JR, Rampton DS
    Editorial: which iron preparation for patients with IBD?
    Aliment Pharmacol Ther. 2017;46:194-195.
    PubMed     Text format    


  190. PORTER CK, Riddle MS, Hooper TI
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st Century. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:64-65.
    PubMed     Text format    


  191. KAPLAN GG
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st century.
    Aliment Pharmacol Ther. 2017;46:63-64.
    PubMed     Text format    


  192. WANG S, Lin J
    Letter: determining the dominant role of environmental factors in UC development.
    Aliment Pharmacol Ther. 2017;46:77-78.
    PubMed     Text format    


    June 2017
  193. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017 Jun 30. doi: 10.1111/apt.14205.
    PubMed     Text format     Abstract available


  194. DERWA Y, Gracie DJ, Hamlin PJ, Ford AC, et al
    Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 27. doi: 10.1111/apt.14203.
    PubMed     Text format     Abstract available


  195. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 14. doi: 10.1111/apt.14173.
    PubMed     Text format     Abstract available


  196. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2017 Jun 8. doi: 10.1111/apt.14167.
    PubMed     Text format     Abstract available


  197. ALEXAKIS C, Kumar S, Saxena S, Pollok R, et al
    Systematic review and meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 2. doi: 10.1111/apt.14171.
    PubMed     Text format     Abstract available


  198. D'HAENS GR, Sandborn WJ, Zou G, Stitt LW, et al
    Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 1. doi: 10.1111/apt.14164.
    PubMed     Text format     Abstract available


  199. STIDHAM RW, Waljee AK
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1551-1552.
    PubMed     Text format    


  200. COLLINS PD
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
    Aliment Pharmacol Ther. 2017;45:1553-1554.
    PubMed     Text format    


  201. HOLT DQ, Moore GT, Strauss BJG, Hamilton AL, et al
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1552-1553.
    PubMed     Text format    


  202. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
    Aliment Pharmacol Ther. 2017;45:1554-1555.
    PubMed     Text format    


  203. VANDE CASTEELE N, Gils A
    Editorial: variability in adalimumab trough and peak serum concentrations.
    Aliment Pharmacol Ther. 2017;45:1475-1476.
    PubMed     Text format    


  204. JAIRATH V, Feagan BG
    Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
    Aliment Pharmacol Ther. 2017;45:1472.
    PubMed     Text format    


  205. BERNSTEIN CN
    Editorial: the impact of the placebo effect in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1471-1472.
    PubMed     Text format    


  206. WARD MG, Gibson PR, Sparrow MP
    Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1476-1477.
    PubMed     Text format    


    May 2017
  207. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Text format     Abstract available


  208. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Text format     Abstract available


  209. CHRISTENSEN B, Sparrow MP
    Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
    Aliment Pharmacol Ther. 2017;45:1274-1275.
    PubMed     Text format    


  210. LAMBA MJ, Tharayil VS, Gearry RB
    Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?
    Aliment Pharmacol Ther. 2017;45:1367-1368.
    PubMed     Text format    


  211. NELSON A, Tsai HH
    Editorial: Clostridium difficile and inflammatory bowel disease - is it always a bad combination?
    Aliment Pharmacol Ther. 2017;45:1368-1369.
    PubMed     Text format    


  212. EVERHOV AH, Olen O, Ludvigsson JF
    Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children.
    Aliment Pharmacol Ther. 2017;45:1369-1370.
    PubMed     Text format    


  213. HAWTHORNE AB
    Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;45:1365-1366.
    PubMed     Text format    


  214. MA C, Fedorak RN, Kaplan GG, Dieleman LA, et al
    Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Aliment Pharmacol Ther. 2017;45:1232-1243.
    PubMed     Text format     Abstract available


  215. HOLT DQ, Moore GT, Strauss BJ, Hamilton AL, et al
    Visceral adiposity predicts post-operative Crohn's disease recurrence.
    Aliment Pharmacol Ther. 2017;45:1255-1264.
    PubMed     Text format     Abstract available


  216. KHORRAMI S, Gisbert JP
    Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.
    Aliment Pharmacol Ther. 2017;45:1374-1375.
    PubMed     Text format    


  217. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1372.
    PubMed     Text format    


  218. FELWICK R, Cummings JRF
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1370-1371.
    PubMed     Text format    


  219. SHIM HH, Seow CH
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
    Aliment Pharmacol Ther. 2017;45:1283-1284.
    PubMed     Text format    


  220. MITREV N, Kariyawasam V, Leong RW
    Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Aliment Pharmacol Ther. 2017;45:1279-1280.
    PubMed     Text format    


  221. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1284.
    PubMed     Text format    


    April 2017
  222. RODA G, Narula N, Pinotti R, Skamnelos A, et al
    Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14063.
    PubMed     Text format     Abstract available


  223. BYE WA, Jairath V, Travis SPL
    Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14075.
    PubMed     Text format     Abstract available


  224. ROBLIN X, Boschetti G, Williet N, Nancey S, et al
    Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14106.
    PubMed     Text format     Abstract available


  225. COUGHLAN A, Wylde R, Lafferty L, Quinn S, et al
    A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14070.
    PubMed     Text format     Abstract available


  226. CRAMER H, Schafer M, Schols M, Kocke J, et al
    Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 5. doi: 10.1111/apt.14062.
    PubMed     Text format     Abstract available


  227. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed     Text format    


  228. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed     Text format    


  229. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed     Text format    


  230. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed     Text format    


  231. YARUR AJ, Kanagala V, Stein DJ, Czul F, et al
    Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:933-940.
    PubMed     Text format     Abstract available


  232. VAN STEENBERGEN S, Bian S, Vermeire S, Van Assche G, et al
    Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Aliment Pharmacol Ther. 2017;45:923-932.
    PubMed     Text format     Abstract available


  233. ALLEN PB, Olivera P, Emery P, Moulin D, et al
    Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
    Aliment Pharmacol Ther. 2017;45:1058-1072.
    PubMed     Text format     Abstract available


  234. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1043-1057.
    PubMed     Text format     Abstract available


  235. WARD MG, Thwaites PA, Beswick L, Hogg J, et al
    Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1135-1145.
    PubMed     Text format     Abstract available


  236. HAMMER T, Lophaven SN, Nielsen KR, von Euler-Chelpin M, et al
    Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
    Aliment Pharmacol Ther. 2017;45:1107-1114.
    PubMed     Text format     Abstract available


  237. JAIRATH V, Zou G, Parker CE, MacDonald JK, et al
    Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1021-1042.
    PubMed     Text format     Abstract available


  238. ANANTHAKRISHNAN AN
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Aliment Pharmacol Ther. 2017;45:1168.
    PubMed     Text format    


  239. VEGH Z, Bessissow T, Afif W, Lakatos PL, et al
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator?
    Aliment Pharmacol Ther. 2017;45:1167.
    PubMed     Text format    


    March 2017
  240. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Text format     Abstract available


  241. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Text format     Abstract available


  242. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Text format     Abstract available


  243. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 6. doi: 10.1111/apt.14023.
    PubMed     Text format     Abstract available


  244. ARTOM M, Czuber-Dochan W, Norton C
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Aliment Pharmacol Ther. 2017;45:763-764.
    PubMed     Text format    


  245. GRACIE DJ, Ford AC
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain.
    Aliment Pharmacol Ther. 2017;45:762-763.
    PubMed     Text format    


  246. HEERASING N, Thompson B, Hendy P, Heap GA, et al
    Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:660-669.
    PubMed     Text format     Abstract available


  247. WINTER RW, Collins E, Cao B, Carrellas M, et al
    Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:653-659.
    PubMed     Text format     Abstract available


  248. SEGAL JP, Ding NS, Worley G, Mclaughlin S, et al
    Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.
    Aliment Pharmacol Ther. 2017;45:581-592.
    PubMed     Text format     Abstract available


  249. RADFORD-SMITH GL, Hartnell F, Doecke JD
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Aliment Pharmacol Ther. 2017;45:856-857.
    PubMed     Text format    


  250. YAMAMOTO T, Shimoyama T
    Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis.
    Aliment Pharmacol Ther. 2017;45:863.
    PubMed     Text format    


  251. FRASER AG
    Editorial: can we get more clinical benefit from thiopurine metabolite testing?
    Aliment Pharmacol Ther. 2017;45:857-858.
    PubMed     Text format    


  252. BARREIRO-DE ACOSTA M, Gisbert JP
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Aliment Pharmacol Ther. 2017;45:855-856.
    PubMed     Text format    


  253. WONG DR, Hooymans PM
    Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:858-859.
    PubMed     Text format    


  254. BEN-HORIN S, Ungar B, Roblin X
    Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:760-762.
    PubMed     Text format    


    February 2017
  255. SMOLINSKA A, Bodelier AG, Dallinga JW, Masclee AA, et al
    The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Feb 26. doi: 10.1111/apt.14004.
    PubMed     Text format     Abstract available


  256. STRIK AS, van den Brink GR, Ponsioen C, Mathot R, et al
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13994.
    PubMed     Text format     Abstract available


  257. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Text format     Abstract available


  258. LOPHAVEN SN, Lynge E, Burisch J
    The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13971.
    PubMed     Text format     Abstract available


  259. LAW CC, Tariq R, Khanna S, Murthy S, et al
    Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 16. doi: 10.1111/apt.13972.
    PubMed     Text format     Abstract available


  260. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 7. doi: 10.1111/apt.13960.
    PubMed     Text format     Abstract available


  261. DOECKE JD, Hartnell F, Bampton P, Bell S, et al
    Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Aliment Pharmacol Ther. 2017;45:542-552.
    PubMed     Text format     Abstract available


  262. FUMERY M, Dulai PS, Meirick P, Farrell AM, et al
    Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.
    Aliment Pharmacol Ther. 2017;45:381-390.
    PubMed     Text format     Abstract available


    January 2017
  263. DIEDEREN K, Hoekman DR, Leek A, Wolters VM, et al
    Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Aliment Pharmacol Ther. 2017 Jan 31. doi: 10.1111/apt.13950.
    PubMed     Text format     Abstract available


  264. VUITTON L, Peyrin-Biroulet L, Colombel JF, Pariente B, et al
    Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
    Aliment Pharmacol Ther. 2017 Jan 23. doi: 10.1111/apt.13948.
    PubMed     Text format     Abstract available


  265. HINDRYCKX P, Novak G, Vande Casteele N, Laukens D, et al
    Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jan 11. doi: 10.1111/apt.13913.
    PubMed     Text format     Abstract available


  266. HARTERY K, O'Reilly S, Houlihan D, Doherty G, et al
    Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2017;45:376-378.
    PubMed     Text format    


  267. HONG SN, Kim HJ, Kim KH, Han SJ, et al
    Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Aliment Pharmacol Ther. 2017;45:253-263.
    PubMed     Text format     Abstract available


  268. GREGOIRE C, Lechanteur C, Briquet A, Baudoux E, et al
    Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:205-221.
    PubMed     Text format     Abstract available


  269. UNGAR B, Kopylov U, Engel T, Yavzori M, et al
    Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Aliment Pharmacol Ther. 2017;45:276-282.
    PubMed     Text format     Abstract available


  270. PRATAP MOULI V, Munot K, Ananthakrishnan A, Kedia S, et al
    Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:27-36.
    PubMed     Text format     Abstract available


  271. CHRISTENSEN B, Sparrow MP
    Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:178-179.
    PubMed     Text format    


    December 2016
  272. ANGELISON L, Almer S, Eriksson A, Karling P, et al
    Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Aliment Pharmacol Ther. 2016 Dec 27. doi: 10.1111/apt.13893.
    PubMed     Text format     Abstract available


  273. CARRAT F, Seksik P, Colombel JF, Peyrin-Biroulet L, et al
    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 19. doi: 10.1111/apt.13897.
    PubMed     Text format     Abstract available


  274. WONG DR, Coenen MJ, Derijks LJ, Vermeulen SH, et al
    Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 12. doi: 10.1111/apt.13879.
    PubMed     Text format     Abstract available


    November 2016
  275. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Text format     Abstract available


  276. ARTOM M, Czuber-Dochan W, Sturt J, Murrells T, et al
    The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.
    Aliment Pharmacol Ther. 2016 Nov 20. doi: 10.1111/apt.13870.
    PubMed     Text format     Abstract available


  277. FEAGAN BG, Patel H, Colombel JF, Rubin DT, et al
    Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Aliment Pharmacol Ther. 2016 Nov 17. doi: 10.1111/apt.13852.
    PubMed     Text format     Abstract available


  278. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Text format     Abstract available


  279. MAO EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13847.
    PubMed     Text format     Abstract available


  280. COLOMBEL JF, Jharap B, Sandborn WJ, Feagan B, et al
    Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Aliment Pharmacol Ther. 2016 Nov 7. doi: 10.1111/apt.13838.
    PubMed     Text format     Abstract available


    October 2016
  281. KIRCHGESNER J, Lemaitre M, Rudnichi A, Racine A, et al
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Aliment Pharmacol Ther. 2016 Oct 26. doi: 10.1111/apt.13835.
    PubMed     Text format     Abstract available


  282. SELINGER CP, Carbery I, Warren V, Rehman AF, et al
    The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Oct 25. doi: 10.1111/apt.13831.
    PubMed     Text format     Abstract available


  283. STALLMACH A, Langbein C, Atreya R, Bruns T, et al
    Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Aliment Pharmacol Ther. 2016 Oct 7. doi: 10.1111/apt.13813.
    PubMed     Text format     Abstract available


    September 2016
  284. D'HAENS G
    Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Sep 21. doi: 10.1111/apt.13803.
    PubMed     Text format     Abstract available


    May 2016
  285. BUISSON A, Vazeille E, Minet-Quinard R, Goutte M, et al
    Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43:1069-79.
    PubMed     Text format     Abstract available


    April 2016
  286. KIRCHGESNER J, Sokol H
    Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Aliment Pharmacol Ther. 2016;43:838-9.
    PubMed     Text format    


  287. TORRES J, Bao X, Goel A, Colombel JF, et al
    The features of mucosa-associated microbiota in primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2016;43:790-801.
    PubMed     Text format     Abstract available


    March 2016
  288. TO N, Gracie DJ, Ford AC
    Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:549-61.
    PubMed     Text format     Abstract available


  289. VEDAK P, Kroshinsky D, St John J, Xavier RJ, et al
    Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
    Aliment Pharmacol Ther. 2016;43:697-704.
    PubMed     Text format     Abstract available


  290. MONTELEONE G, Di Sabatino A, Ardizzone S, Pallone F, et al
    Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:717-24.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: